Metraipolis › archive › dc_8f23665a6791
Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study — Europe PMC PMID:41464721
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41464721
- DOI
- 10.3390/jcm14248819
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T16:25:56.809Z
- SHA-256 of the archived text
ceeffaadef3f0ba3c6e73a311a1ecade286baf41a3662548579c754c337e50f7- Stable URL of this page
https://metraipolis.com/documento/dc_8f23665a6791
How to cite
Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study — Europe PMC PMID:41464721 — Europe PMC (en), https://europepmc.org/article/MED/41464721 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8f23665a6791 (Metraipolis archive dc_8f23665a6791, sha256 ceeffaadef3f0ba3c6e73a311a1ecade286baf41a3662548579c754c337e50f7)
BibTeX
@misc{dc8f23665a6791,
title = {Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study — Europe PMC PMID:41464721},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41464721},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8f23665a6791; sha256 ceeffaadef3f0ba3c6e73a311a1ecade286baf41a3662548579c754c337e50f7},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41464721. Agents can read the archived copy with the MCP tool read_document.